Salbutamol shortage — AU supply status & alternatives

Salbutamol

ATC R03AC02 · Short-acting beta-2 agonist (SABA)

🇦🇺 AUST R 317221 · GlaxoSmithKline Australia Pty Ltd

In shortage · Australia

WHO Essential Medicine

ProAirAiromir VentolinProventil

In declared shortage · 🇦🇺 Australia & also short in🇨🇦 CA🌐 EU🇬🇧 GB🇺🇸 US🇳🇿 NZ🇳🇱 NL

Critical shortage

Reading today’s signals…

🇦🇺 AUAEMPA$2.98DPMQ A$19.14

Product attributes reference data we hold

Active ingredient (INN)	Salbutamol
Brand names	ProAir, Airomir, Ventolin, Proventil
ATC level 5	R03AC02
ATC level 4	R03AC
Drug class	Short-acting beta-2 agonist (SABA)
Therapeutic category	Respiratory
Strength	100mcg/dose · 2.5mg/2.5ml nebules · 4mg tablet · 500mcg/ml IV
Dosage form	pressurised inhaler · nebuliser solution · tablet · solution for injection
Route of administration	inhaled · oral · intravenous · subcutaneous
WHO Essential Medicine	Yes (2023)
Controlled substance	No
Marketing-authorisation holders	GlaxoSmithKline Australia Pty Ltd, ACCORD-UK LIMITED, TEVA UK LIMITED, ORION CORPORATION +7 more
Registrations on file	29
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$2.98

AEMP

Dispensed (DPMQ)

A$19.14

incl. fees

Pack

salbutamol 2.5 mg/2.5 mL inhalation solution, 20 x 2.5 mL ampoules

pressurised inhaler

Source: PBSEffective July 2026 · AUD

Other markets

🇪🇸 ES

€2.81

Retail price

🇫🇷 FR

€18.09

Retail price

🇬🇧 GB

£1.97

Drug Tariff

Substitution pathways 🇦🇺 Australia · TGA

✓

Section 19A approval in force · salbutamol-sulfate-5mg25ml-nebuliser-solution-ampoule-accord-uk

TGA Section 19A: overseas-registered 'Salbutamol (as sulfate) 5mg/2.5ml Nebuliser Solution ampoule (Accord, UK)' approved for import and supply in Australia during a shortage. Origin: Accord, UK. Expires July 2026. Verify on TGA Section 19A approvals ↗

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 2h ago

Critical

🇨🇦

Canada

Medsafe NZ Full · 3mo ago

High

🇺🇸

United States

FDA MedWatch · 1mo ago

High

🇳🇿

New Zealand

Pharmac · 4h ago

High

🇬🇧

United Kingdom

MHRA · 8h ago

High

🌐

EMA · 1d ago

High

🇳🇱

Netherlands

CBG-MEB · 3h ago

Medium

🇪🇸

Spain

AEMPS · 1mo ago

Resolved

Sources official regulators

🇨🇦

verified 2h ago

verify ↗

🇺🇸

FDA

verified 2h ago

verify ↗

🇦🇺

TGA

verified 2h ago

verify ↗

🇳🇱

CBG-MEB

verified 3h ago

verify ↗

🇳🇿

Pharmac

verified 4h ago

verify ↗

🇬🇧

MHRA

verified 8h ago

verify ↗

🌐

EMA

verified 1d ago

verify ↗

🇳🇿

Medsafe NZ Full

verified 3mo ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders29 registrations · 11 MA holders

Product	Strength	Form	Market	MA holder	Status
VENTOLIN INHALER CFC-Free Salbutamol	100 microgram	—	🇦🇺 AU	GlaxoSmithKline Australia Pty Ltd	Active
Salbutamol Tablets Bp	2MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
Salbutamol Tablets Bp	4MG	tablet	🇬🇧 GB	ACCORD-UK LIMITED	Active
SALBUTAMOL 2.5MG/2.5ML NEBULISER SOLUTION	2.5MG	solution	🇬🇧 GB	ACCORD-UK LIMITED	Active
SALBUTAMOL 5MG/2.5ML NEBULISER SOLUTION	5MG	solution	🇬🇧 GB	ACCORD-UK LIMITED	Active
SALBUTAMOL 2.5 MG/2.5 ML NEBULISER SOLUTION	2.5 MG	solution	🇬🇧 GB	TEVA UK LIMITED	Active
SALBUTAMOL 5 MG/2.5 ML NEBULISER SOLUTION	5 MG	solution	🇬🇧 GB	TEVA UK LIMITED	Active
Easyhaler Salbutamol Sulfate	100 MICROGRAM	powder	🇬🇧 GB	ORION CORPORATION	Active
Easyhaler Salbutamol Sulfate	200 MCG	powder	🇬🇧 GB	ORION CORPORATION	Active
Salbutamol Neutec	2.5 MG	solution	🇬🇧 GB	NEUTEC INHALER IRELAND LIMITED	Active
Ipratropium Bromide/Salbutamol Neutec	0.5 MG	solution	🇬🇧 GB	NEUTEC INHALER IRELAND LIMITED	Active
SALBUTAMOL 1MG /ML NEBULISER SOLUTION	1MG	solution	🇬🇧 GB	CIPLA (EU) LIMITED	Active
SALBUTAMOL 2MG /ML NEBULISER SOLUTION	2MG	solution	🇬🇧 GB	CIPLA (EU) LIMITED	Active
VENTOLIN salbutamol 500microgram/	500microgram	—	🇦🇺 AU	GlaxoSmithKline Australia Pty Ltd	Active
VENTOLIN OBSTETRIC salbutamol	5mg	—	🇦🇺 AU	GlaxoSmithKline Australia Pty Ltd	Active

+14 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.